BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32248340)

  • 1. Blue Light Cystoscopy: Indications and Outcomes.
    Pohar KS
    Curr Urol Rep; 2020 Apr; 21(5):19. PubMed ID: 32248340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
    Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
    BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer.
    Yang LP
    Mol Diagn Ther; 2014 Feb; 18(1):105-16. PubMed ID: 24248555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.
    Daneshmand S; Schuckman AK; Bochner BH; Cookson MS; Downs TM; Gomella LG; Grossman HB; Kamat AM; Konety BR; Lee CT; Pohar KS; Pruthi RS; Resnick MJ; Smith ND; Witjes JA; Schoenberg MP; Steinberg GD
    Nat Rev Urol; 2014 Oct; 11(10):589-96. PubMed ID: 25245244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
    Rose JB; Armstrong S; Hermann GG; Kjellberg J; Malmström PU
    BJU Int; 2016 Jun; 117(6B):E102-13. PubMed ID: 26305667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis.
    Capece M; Spirito L; La Rocca R; Napolitano L; Buonopane R; Di Meo S; Sodo M; Bracale U; Longo N; Palmieri A; Fusco F; Verze P; Califano G; Crocetto F; Imbimbo C; Mirone V; Imperatore V; Creta M
    Arch Ital Urol Androl; 2020 Apr; 92(1):17-20. PubMed ID: 32255316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.
    Lotan Y; Bivalacqua TJ; Downs T; Huang W; Jones J; Kamat AM; Konety B; Malmström PU; McKiernan J; O'Donnell M; Patel S; Pohar K; Resnick M; Sankin A; Smith A; Steinberg G; Trabulsi E; Woods M; Daneshmand S
    Nat Rev Urol; 2019 Jun; 16(6):377-386. PubMed ID: 31019310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Blue Light Cystoscopy on the Diagnosis and Treatment of Bladder Cancer.
    Pietzak EJ
    Curr Urol Rep; 2017 May; 18(5):39. PubMed ID: 28324275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data.
    Witjes JA; Gomella LG; Stenzl A; Chang SS; Zaak D; Grossman HB
    Urology; 2014 Jul; 84(1):122-6. PubMed ID: 24768013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Initial experience in the diagnosis and treatment of superficial bladder tumors with Hexvix].
    Abascal Junquera JM; Hevia Suárez M; Abascal García JM; Estébanez C; Astudillo A; Abascal R
    Arch Esp Urol; 2008 May; 61(4):475-82; discussion 482-3. PubMed ID: 18592765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
    Burger M; Grossman HB; Droller M; Schmidbauer J; Hermann G; Drăgoescu O; Ray E; Fradet Y; Karl A; Burgués JP; Witjes JA; Stenzl A; Jichlinski P; Jocham D
    Eur Urol; 2013 Nov; 64(5):846-54. PubMed ID: 23602406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macro and microeconomics of blue light cystoscopy with CYSVIEW® in non-muscle invasive bladder cancer.
    Williams SB; Gavaghan MB; Fernandez A; Daneshmand S; Kamat AM
    Urol Oncol; 2022 Jan; 40(1):10.e7-10.e12. PubMed ID: 34158205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer: cost consequences during outpatient surveillance in Sweden.
    Dansk V; Malmström PU; Bläckberg M; Malmenäs M
    Future Oncol; 2016; 12(8):1025-38. PubMed ID: 26975197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
    O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
    BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials.
    Zhao H; Peng P; Luo Z; Liu H; Sun J; Wang X; Jia Q; Yang Z
    Photodiagnosis Photodyn Ther; 2023 Mar; 41():103220. PubMed ID: 36462704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the management of bladder cancer with fluorescence cystoscopy.
    Grossman HB
    J Environ Pathol Toxicol Oncol; 2007; 26(2):143-7. PubMed ID: 17725540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance.
    Malmström PU; Grabe M; Haug ES; Hellström P; Hermann GG; Mogensen K; Raitanen M; Wahlqvist R
    Scand J Urol Nephrol; 2012 Apr; 46(2):108-16. PubMed ID: 22087730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blue light cystoscopy with hexylaminolevulinate: Our 7 years experience.
    Lacetera V; Cantoro U; Montesi L; Cantoro D; Cervelli B; Cicetti A; Gabrielloni G; Milella D; Montesi M; Morcellini R; Parri G; Recanatini E; Beatrici V
    Arch Ital Urol Androl; 2017 Mar; 89(1):39-41. PubMed ID: 28403596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.
    Jocham D; Witjes F; Wagner S; Zeylemaker B; van Moorselaar J; Grimm MO; Muschter R; Popken G; König F; Knüchel R; Kurth KH
    J Urol; 2005 Sep; 174(3):862-6; discussion 866. PubMed ID: 16093971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.